| Page 168 | Aplastic Anemia and MDS International Foundation

The genetic basis of myelodysplastic syndromes.

Author(s): 
Bejar R, Ebert BL
Primary Author: 
Bejar R
Journal Title: 
Hematol Oncol Clin North Am
Original Publication Date: 
Apr 2010

Myelodysplastic syndrome (MDS) disorders are clonal diseases that often carry stereotypic chromosomal abnormalities. A smaller proportion of cases harbor point mutations that activate oncogenes or inactivate tumor suppressor genes. New technologies have accelerated the pace of discovery and are responsible for the identification of novel genetic mutations associated with MDS and other myeloid neoplasms. These discoveries have identified novel mechanisms in the pathogenesis of MDS. This article touches on the better known genetic abnormalities in MDS

Bone Marrow Diseases: 

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

Author(s): 
Steensma DP, Stone RM
Primary Author: 
Steensma DP
Journal Title: 
Hematol Oncol Clin North Am
Original Publication Date: 
Apr 2010

Clinicians commonly administer one or the other of the two hypomethylating agents currently approved in the United States--

Bone Marrow Diseases: